Literature DB >> 15388478

AmpC beta-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins.

Hedi Mammeri1, Hasan Nazic, Thierry Naas, Laurent Poirel, Sophie Léotard, Patrice Nordmann.   

Abstract

Cloning, sequencing, and biochemical analysis identified a novel AmpC-type beta-lactamase conferring resistance to extended-spectrum cephalosporins in an Escherichia coli clinical isolate. This enzyme, exhibiting 14 amino acid substitutions compared to a reference AmpC cephalosporinase of E. coli, hydrolyzed ceftazidime and cefepime significantly.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15388478      PMCID： PMC521871          DOI： 10.1128/AAC.48.10.4050-4053.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

Review 1.  Plasmid-determined AmpC-type beta-lactamases.

Authors:  Alain Philippon; Guillaume Arlet; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

2.  Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs.

Authors:  T Spanu; F Luzzaro; M Perilli; G Amicosante; A Toniolo; G Fadda
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  Analysis of the effects of -42 and -32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing ampC.

Authors:  N Caroff; E Espaze; D Gautreau; H Richet; A Reynaud
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

Review 4.  AmpC beta-lactamases: what do we need to know for the future?

Authors:  Nancy D Hanson
Journal:  J Antimicrob Chemother       Date:  2003-05-29       Impact factor: 5.790

5.  Experimental prediction of the evolution of cefepime resistance from the CMY-2 AmpC beta-lactamase.

Authors:  Miriam Barlow; Barry G Hall
Journal:  Genetics       Date:  2003-05       Impact factor: 4.562

6.  Decreased susceptibility to cefepime in a clinical strain of Escherichia coli related to plasmid- and integron-encoded OXA-30 beta-lactamase.

Authors:  Véronique Dubois; Corinne Arpin; Claudine Quentin; Jeannette Texier-Maugein; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

7.  Mutation in Serratia marcescens AmpC beta-lactamase producing high-level resistance to ceftazidime and cefpirome.

Authors:  A Raimondi; F Sisto; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

8.  Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate.

Authors:  G Barnaud; R Labia; L Raskine; M J Sanson-Le Pors; A Philippon; G Arlet
Journal:  FEMS Microbiol Lett       Date:  2001-02-20       Impact factor: 2.742

9.  Broad resistance due to plasmid-mediated AmpC beta-lactamases in clinical isolates of Escherichia coli.

Authors:  R Odeh; S Kelkar; A M Hujer; R A Bonomo; P C Schreckenberger; J P Quinn
Journal:  Clin Infect Dis       Date:  2002-06-24       Impact factor: 9.079

10.  Three-dimensional structure of AmpC beta-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design.

Authors:  K C Usher; L C Blaszczak; G S Weston; B K Shoichet; S J Remington
Journal:  Biochemistry       Date:  1998-11-17       Impact factor: 3.162
View more
  11 in total

1.  Exact location of the region responsible for the extended substrate spectrum in class C beta-lactamases.

Authors:  Sang Hee Lee; Jung Hun Lee; Myong Jin Heo; Il Kwon Bae; Seok Hoon Jeong; Sun-Shin Cha
Journal:  Antimicrob Agents Chemother       Date:  2007-10       Impact factor: 5.191

2.  Naturally occurring extended-spectrum cephalosporinases in Escherichia coli.

Authors:  Hedi Mammeri; Laurent Poirel; Nicolas Fortineau; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Ciprofloxacin-resistant Escherichia coli in hospital wastewater of Bangladesh and prediction of its mechanism of resistance.

Authors:  Farhima Akter; M Ruhul Amin; Khan Tanjid Osman; M Nural Anwar; M Manjurul Karim; M Anwar Hossain
Journal:  World J Microbiol Biotechnol       Date:  2011-09-09       Impact factor: 3.312

4.  Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum beta-lactamase AmpC.

Authors:  Hélène Guillon; Didier Tande; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2011-07-11       Impact factor: 5.191

5.  Hydrolysis spectrum extension of CMY-2-like β-lactamases resulting from structural alteration in the Y-X-N loop.

Authors:  Sandrine Dahyot; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

Review 6.  Class C β-Lactamases: Molecular Characteristics.

Authors:  Alain Philippon; Guillaume Arlet; Roger Labia; Bogdan I Iorga
Journal:  Clin Microbiol Rev       Date:  2022-04-18       Impact factor: 50.129

7.  Structural Insights into Inhibition of the Acinetobacter-Derived Cephalosporinase ADC-7 by Ceftazidime and Its Boronic Acid Transition State Analog.

Authors:  Brandy N Curtis; Kali A Smolen; Sara J Barlow; Emilia Caselli; Fabio Prati; Magdalena A Taracila; Robert A Bonomo; Bradley J Wallar; Rachel A Powers
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

Review 8.  AmpC beta-lactamases.

Authors:  George A Jacoby
Journal:  Clin Microbiol Rev       Date:  2009-01       Impact factor: 26.132

9.  Emergence of co-production of plasmid-mediated AmpC beta-lactamase and ESBL in cefoxitin-resistant uropathogenic Escherichia coli.

Authors:  B Ghosh; M Mukherjee
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-02       Impact factor: 3.267

10.  New disturbing trend in antimicrobial resistance of gram-negative pathogens.

Authors:  Jung Hun Lee; Seok Hoon Jeong; Sun-Shin Cha; Sang Hee Lee
Journal:  PLoS Pathog       Date:  2009-03-27       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.